Please note that you will not need to register for the EANO Meeting 2023 in order to participate in this symposium virtually
On-site participation is only available to those who have registered to attend the EANO Meeting.
Isocitrate dehydrogenase (IDH) mutations have been recognised as an oncogenic driver in gliomas for more than a decade and in recent years there has been a growing focus on IDH mutations as a potential therapeutic target. In this educational symposium the exciting recent clinical data with IDH mutation inhibitors in glioma are shared and the impact of new therapies on the clinical management of glioma patients are discussed by leading international experts in glioma treatment.
We cordially invite you to join us for this exciting symposium at the 2023 EANO Meeting which will review the latest data and the implications for patients with these challenging tumours.
The symposium will end with a Q&A session with the faculty.
This symposium is initiated, organised, and funded by Servier.